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Abstract
BACKGROUND—Telomerase reverse transcriptase (TERT) promoter mutations that may affect 
telomerase activity have recently been described in human malignancies. The purpose of this study 
was to investigate the clinical correlates of TERT promoter abnormalities in a large cohort of 
patients with diverse cancers.
METHODS—This study analyzed TERT promoter alterations and clinical characteristics of 423 
consecutive patients for whom molecular testing by next-generation sequencing was performed 
between August 2014 and July 2015.
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RESULTS—Of the 423 patients, 61 (14.4%) had TERT promoter mutations, and this placed 
TERT promoter alterations among the most prevalent aberrations after tumor protein 53 (TP53; 
39%) and KRAS and cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) alterations (15% 
each) in this population. TERT promoter alterations were more frequent in men (P=.031) and were 
associated with brain cancers (P=.001), skin cancers/melanoma (P=.001), and a higher number of 
aberrations (P=.0001). A co-alteration analysis found that TERT promoter alterations were 
significantly correlated with CDKN2A/B (P=.001) and BRAF abnormalities (P=.0003). Patients 
harboring TERT promoter alterations or TP53 or CDKN2A/B alterations and those with 4 or more 
alterations demonstrated shorter survival (hazard ratio for normal TERT promoters vs aberrant 
ones, 0.44; P=.017). However, only a higher number of alterations remained significant in the 
multivariate analysis.
CONCLUSIONS—Overall, TERT promoter alterations were among the most prevalent 
aberrations in this population, with very high rates in brain cancers (48% of patients) and 
melanomas (56% of patients). These aberrations frequently coexist with a high number of other 
aberrations, with the latter feature also significantly associated with poorer overall survival. 
Therapeutic options for targeting tumors with TERT promoter mutations are currently limited, 
although a variety of novel approaches are under development.
Keywords
BRAF; glioblastoma; melanomas; next-generation sequencing; survival; telomerase reverse 
transcriptase (TERT) promoter mutations
INTRODUCTION
Cancer is driven by molecular aberrations allowing oncogenic cells to thrive by growing and 
eventually metastasizing. Research studies investigating oncogenic mechanisms have 
highlighted the strategies that cancer cells can develop to survive by manipulating pathways 
conferring a selective growth advantage to the tumor. Examples of such acquired 
mechanisms include sustaining proliferative signaling, evading growth suppressors, resisting 
cell death, inducing angiogenesis, activating invasion and metastasis, and enabling 
replicative immortality.1 Indeed, in addition to the accumulation of mutations conferring a 
selective growth advantage, malignant cells can acquire aberrations leading to immortality.
In 1995, Chadeneau et al2 demonstrated that telomerase, the enzyme that elongates 
telomeric DNA, was present in human cells immortalized in vitro and in metastatic ovarian 
and colorectal carcinomas but not in normal tissue. Telomeres are present at the ends of 
eukaryotic chromosomes and are composed of simple, repetitive G-rich sequences. 
Telomerase reverse transcriptase (TERT) is a catalytic subunit of the telomerase enzyme 
responsible for catalyzing the addition of nucleotides to the end of a chromosome’s 
telomeres.3 In normal cells, the shortening of telomeres has the ability to activate the 
senescence pathway, or the loss of a cell’s power of division and growth.4,5 In parallel, it has 
been demonstrated that telomere length stabilization by telomerase would allow unlimited 
proliferation.3 It has, therefore, been hypothesized that telomeres hold an important key to 
both aging and cancer.6
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Reactivation or re-expression of telomerase is believed to be a widespread feature of human 
cancers, although its genetic basis remains poorly understood.7 Although it appears that 
somatic mutations in the coding region of TERT are rather infrequent in cancer, somatic 
mutations in the TERT promoter region have been described in several specific types of 
human cancers (eg, glioblastoma, bladder cancer, thyroid cancer, and skin cancer), and they 
lead to increased telomerase expression.8,9 Mutations within the promoter region of TERT 
that confer enhanced TERT promoter activity have been reported in 2 major hotspots, which 
are located at –124 and –146 base pairs upstream of the transcriptional start site (also 
designated C228T and C250T, respectively).8,10,11 Interestingly, mutations in the TERT 
promoter region, as opposed to the coding region, allow the creation of additional binding 
sites for transcription factors and may represent a novel mechanism of oncogenic activation 
in cancer.
Our study objectives were to investigate the frequency of TERT promoter mutations in our 
population of patients with diverse cancer types and to delineate correlations with other 
clinical parameters.
MATERIALS AND METHODS
Patients
We retrospectively reviewed the characteristics and clinical outcomes of 423 consecutive 
patients for whom molecular testing had been performed between August 2014 and July 
2015 and who had been seen at the Moores Cancer Center (University of California San 
Diego). This study was performed and consent was obtained in accordance with the 
institutional review board guidelines of the University of California San Diego.
Next-Generation Sequencing
Next-generation sequencing was performed with Foundatio-nOne (Foundation Medicine, 
Cambridge, Massachusetts), which is a Clinical Laboratory Improvement Amendments–
approved clinical-grade next-generation sequencing test that interrogates 315 cancer-related 
genes plus introns from 28 genes often rearranged or altered in cancer to a typical median 
depth of coverage greater than 500 × (the full list is available at http://
www.foundationone.com/learn.php#2). This test can detect base substitutions, insertions and 
deletions, copy number alterations, and rearrangements from a routine tissue sample 
(including core or fine-needle biopsies).
Statistical Analysis
Patients’ baseline characteristics were presented with descriptive statistics. Associations 
between categorical variables were evaluated with Fisher’s exact test, whereas association 
testing for continuous dependent variables used the Mann-Whitney test. Multiple logistic 
regressions (multivariate analysis) were fit to analyze the association between TERT 
promoter mutations and other patient characteristics. Overall survival was defined as the 
time from diagnosis to death or the last follow-up date for patients who were alive. Patients 
still alive at the last follow-up were censored at that date. Estimations for overall survival 
were performed with a Kaplan-Meier analysis and were compared among subgroups by the 
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log-rank test. The Cox regression model was fit to assess the association between overall 
survival and multiple other patient characteristics (covariables). Unless otherwise specified, 
only variables with P values ≤ .05 were included in the multivariate models. All statistical 
analyses were performed by one of the authors (Maria Schwaederle) with SPSS version 
22.0.
RESULTS
Patient Characteristics
The medical records of 423 consecutive patients who were seen at the Moores Cancer 
Center (University of California San Diego) and had comprehensive molecular testing 
performed were reviewed and analyzed. There was a slight preponderance of women over 
men (54% vs 46%). The median age at diagnosis was 57.2 years (95% confidence interval, 
55.1–58.5 years). The majority of our patients were white (69%); the next most common 
ethnicity was Asian (10.4%). The most common primary tumor sites were gastrointestinal 
(30.3%); they were followed by hematologic malignancies (11.6%), breast cancer (10.9%), 
brain cancer (10.4%), lung cancer (10.2%), and skin cancer/melanoma (8%). The median 
number of alterations per patient was 4.0 (range, 0–22; Table 1).
TERT Promoter Alterations and Correlation Analysis
In the overall population, 61 patients (14.4%) had a TERT promoter mutation, and this 
placed TERT promoter alterations among the most prevalent aberrations after tumor protein 
53 alterations (TP53; 39%) and KRAS and cyclin-dependent kinase inhibitor 2A/B 
(CDKN2A/B) alterations (15% each) in our population including diverse cancer types (Fig. 
1A). Forty-three of 61 patients (70.5%) carried TERT promoter –124 C>T alterations, 14 
patients (23%) carried 146 C>T alterations, and 4 patients (6.6%) carried 124–125 CC>TT 
or 138–139 CC>TT alterations (2 patients each).
In a univariate analysis, TERT promoter alterations were found more often in men (21.5%) 
than women (8.3%), and they were associated with brain (P <.0001), skin/melanoma (P <.
0001), and head and neck tumors (P =.045). On the other hand, TERT promoter alterations 
were significantly less commonly observed in gastrointestinal, hematologic, breast, and lung 
cancers. Interestingly, TERT promoter alterations were significantly associated with an 
increased median number of alterations (5 vs 3; P <.0001; Table 1). We also observed a 
trend toward an association with an older median age at diagnosis (59.1 vs 56.7 years; P =.
060).
To consider potential confounders, we consecutively performed a multivariate analysis, 
which confirmed that TERT promoter alterations correlated with men (P =.031), brain 
cancers (P =.001), skin cancer/melanoma (P =.001), and a higher number of aberrations (P 
=.0001; Table 2). Indeed, TERT promoter alterations were the most frequent alterations 
detected in patients with brain cancers (48% of whom harbored these alterations), and they 
were followed by TP53 alterations (34%) and phosphatase and tensin homolog (PTEN) 
abnormalities (30%; Fig. 1B). Similarly, 56% of patients with a skin/melanoma malignancy 
carried a TERT promoter mutation, and this made the gene the most frequently altered, with 
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TP53 (38%) and CDKN2A/B alterations being in the second and third positions, 
respectively (Fig. 1C). Even though it was just a trend in the multivariate analysis (P =.184), 
it is worth mentioning that 29% of the patients with head and neck cancers harbored a TERT 
promoter mutation (Fig. 1D).
For 2 patients with ependymoma, TERT promoter mutations were observed as single 
alterations, and the patients were still alive after being diagnosed in 2001 and 2003, 
respectively.
Co-Alteration Analysis
We next investigated the possible associations of TERT promoter alterations with other 
alterations, and we found that TERT promoter alterations were significantly associated with 
CDKN2A/B, PTEN, neurofibromin 1 (NF1), and BRAF alterations in a univariate analysis 
(all P values ≤.004; Table 3). Once adjustments were made for potential confounding 
variables in a multivariate analysis including brain and skin/melanoma primary tumor sites, 
only CDKN2A/B (P =.001) and BRAF alterations (P =.0003) remained independently 
associated with TERT promoter alterations.
When we focused only on patients with brain tumors (n =44), TERT promoter alterations 
were associated with epidermal growth factor receptor (EGFR) alterations (33% vs 4.3%; P 
=.019), CDKN2A/B alterations (43% vs 4.3%; P =.003), and PTEN alterations (48% vs 
13%; P =.020). Although it was not statistically significant, the co-occurrence of TERT 
promoter alterations was less frequent in patients with TP53 alterations (19% vs 34%; P =.
060). However, none of these associations remained statistically significant in the multiple 
logistic regression model including the alterations with P <.1 in the univariate analysis.
In patients with skin/melanoma tumors (n =34), we could detect an association between 
TERT promoter alterations and BRAF alterations (37% vs 7%) in the multivariate model 
including the alterations with P <.1 in the univariate analysis.
Overall Survival
A log-rank test (univariate) highlighted significantly shorter overall survival for patients 
harboring TERT promoter alterations in the overall population (P =.01) as well as TP53 or 
CDKN2A/B alterations. In addition, patients with 4 or more alterations (4 alterations being 
the median in the overall population) also demonstrated significantly shorter overall survival. 
The median overall survival from diagnosis was still not reached at the time of our analysis 
(median follow-up, 27.3 months). In the Cox regression model (multivariate analysis), only 
4 or more alterations remained an independent prognostic factor associated with shorter 
survival (Table 4). Interestingly, subanalyses of the 3 tumor types with the highest 
prevalence of TERT alterations demonstrated consistently shorter survival (or a trend toward 
shorter survival) for patients with altered TERT promoters in brain tumors (n =44; P =.037), 
head and neck cancers (n =28; P =.2), or melanoma/skin tumors (n =34; P =.15).
Schwaederle et al. Page 5
Cancer. Author manuscript; available in PMC 2018 March 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
DISCUSSION
The TERT gene encodes the reverse transcriptase component of the telomerase complex, 
which is necessary for telomere stabilization and cell immortalization. Recently, TERT 
promoter mutations have been reported in human malignancies; they create de novo ETS1-
binding motifs upregulating TERT messenger RNA and telomerase activity in malignant 
cells.8,10,13,14
In our study population, 61 patients (14.4%) had a TERT promoter mutation, and this placed 
TERT promoter alterations among the most prevalent aberrations after TP53 (39%). In the 
multivariate analysis, TERT promoter alterations were more frequent in men (21.5% of men 
and 8.3% of women had an alteration; P =.031) and were associated with brain tumors (48% 
of patients; P =.001) and skin cancer/melanoma (56% of patients; P =.001; Table 2). In 
previous studies, TERT promoter mutations were found to be the most common point 
mutations in several tumor types, including glioblastoma (83%),15 melanoma (71%),10,11 
bladder cancer (66%),16 and hepatocellular carcinoma (47%).17 Interestingly, in a recent 
study investigating the mutational landscape of metastatic cancer in an extensive cohort 
(10,000 patients), Zehir et al18 found a very similar frequency of TERT alterations in their 
population covering different tumor types (approximately 15%). In our study, there was also 
a trend toward an association with older patients in the univariate analysis but not in the 
multivariate analysis. The latter is consistent with other studies in which there has been an 
association between TERT promoter alterations and increased age.8,15,19
In univariate analyses, survival was significantly shorter for patients harboring TERT 
promoter alterations in the overall population (P =.017) and also for patients with brain 
tumors (P =.037; Fig. 2A). Although it did not reach statistical significance, perhaps because 
of the limited number of patients, we also observed a trend toward shorter survival in 
individuals with melanoma and head and neck tumors (Fig. 2B,C). Similarly, Zehir et al18 
described poorer survival with several tumor types for patients harboring TERT promoter 
alterations (cutaneous melanoma, papillary thyroid cancer, and bladder urothelial 
carcinoma); however, it was statistically significant in the univariate analysis only for 
bladder urothelial carcinoma. In addition, the presence of TERT promoter mutations was 
previously associated with decreased overall survival in several other studies examining 
thyroid cancer,20 urogenital cancer,21 melanoma,22 laryngeal tumors,23 and glioblastomas.
19,24
 However, in our study, only a higher number of alterations was retained as a significant 
independent variable correlating with survival in the multivariate analysis. Finally, TERT 
promoter mutations were associated with alterations in CDKN2A, and the latter anomalies 
have also been associated with a poor prognosis.25,26 TERT promoter alterations were 
significantly associated with an increased median number of alterations (5 vs 3; P <.0001) in 
our population. These results may be of importance because a larger total number of 
aberrations is of prognostic value in several tumor types, with more aberrations predicting 
shorter progression-free survival.27–29
In our study, 48% of the patients with brain tumors had the TERT promoter mutation, and 
patients with these alterations had shorter survival (Fig. 2A). TERT promoter mutations have 
been reported in 55% to 84% of glioblastomas and have been associated with increased 
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TERT expression.19,30,31 The prevalence of TERT promoter mutations is lower in pediatric 
patients with glioblastomas (approximately 11%).32 In agreement with our findings, in brain 
tumors, TERT promoter mutations have been associated with EGFR amplification and 
inversely correlated with altered TP53.33 However, these associations were not maintained 
in the multivariate analysis. Labussiere et al19 showed that TERT promoter mutations were 
an independent factor associated with a poor prognosis in glioblastomas (overall survival, 
13.8 vs 18.4 months), as were older age and EGFR amplification. In addition, TERT 
promoter mutations were associated with shorter overall survival for patients with primary 
glioblastomas in another study (11 vs 20 months [P =.002] and 12 vs 20 months [P =.04] for 
C228T and C250T, respectively).34 Recently, a new molecular classification of gliomas 
using the TERT promoter mutation status has been reported to be highly predictive for 
survival.24
Overall, 56% of the patients with a skin/melanoma malignancy carried a TERT promoter 
mutation in our analysis. The –146 C>T mutation is the previously reported most frequently 
detected somatic base change in the TERT promoter.8,10 In our skin cancer/melanoma 
population (as in our overall cancer population), –124 C>T was the most frequent somatic 
base change, with 8 of 19 TERT promoter–altered skin/melanoma tumors (42%) harboring 
this specific base change, whereas only 6 patients (31.6%) had a –146 C>T base change. 
TERT promoter alterations are associated with poorer survival for patients with cutaneous 
melanomas.22 In patients with skin/melanoma tumors (n =34), there was an association 
between TERT promoter alterations and BRAF alterations (37% vs 7%). There was only 1 
melanoma patient with a concurrent non–BRAF V600 mutation (a BRAF G466E mutation). 
Macerola et al35 showed the association between TERT promoter and BRAF mutations to be 
an independent poor prognostic factor. Vinagre et al8 also demonstrated that TERT 
messenger RNA levels are higher when TERT promoter and BRAF mutations coexist in 
melanomas. There is some evidence that BRAF mutations coexisting with TERT promoter 
mutations are associated with aggressive behavior in papillary thyroid cancers.36
Interestingly, 29% of the patients with head and neck cancers in our cohort had the TERT 
promoter mutation. TERT promoter mutations are predictive of worse survival for patients 
with laryngeal cancer.23 In our study population, urothelial cancers accounted for only 3% 
of the cancers, with 3 of 13 having a TERT promoter mutation. TERT mutations are frequent 
in both noninvasive and invasive bladder tumors.31,37
Tumor types with high levels of TERT promoter alterations almost always originate in 
tissues with relatively low rates of self-renewal (eg, melanomas and gliomas).15 It is 
speculated that TERT promoter mutations in these cancers maintain telomerase at levels that 
may lead to immortalization or at least prolong shortening of telomere length and 
senescence.38,39 This may explain the observed lack of TERT promoter mutations in 
gastrointestinal cancers (that continually self-renew) other than hepatocellular cancer.15,17
Our study has some limitations. Most of our analysis evaluated patients with diverse cancers, 
although it is possible that this suggests generalizability of the observations across tumor 
types. Several subanalyses were performed in specific tumor types; the smaller number of 
patients in these subanalyses may have diminished the statistical power. For some other 
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cancer types of interest such as those in the bladder, there were only a small number of 
patient specimens available, and statistical analysis in this subgroup was not feasible.
Therapeutic options for targeting tumors with TERT promoter mutations are currently 
limited, although a variety of treatment approaches to affecting TERT are under 
development, including immunotherapies that use TERT as a tumor-associated antigen.40 
Common aberrations that coexist with TERT promoter mutations include BRAF and 
CDKN2A/B anomalies. Further work is needed to ascertain the responses to BRAF 
inhibitors in the presence of coexisting TERT promoter mutations. TERT promoter 
mutations lead to increased telomerase activity, which can be targeted with inhibitors.41,42 In 
addition, the transcription factor GABPA/B can bind to and activate the TERT promoter.43 
Therefore, combinations of experimental drugs that target this pathway and coexisting 
molecular aberrations can also be explored.
In conclusion, abnormalities in the TERT promoter are frequent across diverse cancers, with 
14.4% of our patients harboring these aberrations; this makes aberrations in the TERT 
promoter among the most prevalent aberrations after TP53 (39% of patients) and KRAS and 
CDKN2A/B alterations (15% each) in our population. TERT promoter alterations were more 
frequent in men and were associated with brain, skin/melanoma, and head and neck tumors. 
Conversely, TERT promoter alterations were significantly less commonly observed in 
gastrointestinal, hematologic, breast, and lung cancers. TERT promoter mutations were 
associated with higher numbers of alterations, and this feature correlated with poorer 
survival. Targeting TERT and telomerase should be a goal of future studies.
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Figure 1. 
Gene alteration frequencies. The bar graphs show the frequencies of the most common genes 
in the most represented tumor types. Only TERT promoter alterations have been tested and 
included. (A) Genes with 20 or more patients carrying the alteration are shown. (B–D) 
Genes with 5 or more patients carrying the alteration are shown. APC indicates adenomatous 
polyposis coli; ARID, AT-rich interaction domain; CDK4, cyclin-dependent kinase 4; 
CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; EGFR, epidermal growth factor 
receptor; MLL2, mixed-lineage leukemia 2; NF1, neurofibromin 1; NOTCH1, notch 
homolog 1; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α; 
PTEN, phosphatase and tensin homolog; TERT, telomerase reverse transcriptase; TP53, 
tumor protein 53.
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Figure 2. 
Kaplan-Meier curves for (A) brain tumors, (B) head and neck cancers, and (C) skin/
melanoma tumors from the date of diagnosis. The log-rank test was used to compare 
variables. TERT indicates telomerase reverse transcriptase.
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TABLE 1
Patient Characteristics
Characteristic
Total Patients (n =423 
[100%])
TERT Promoter 
Alterations (n =61 
[14.4%])
TERT Promoter Wild 
Type (n =362 [85.6%]) P (Univariate)a
Age at diagnosis, median (95% 
CI), y
57.2 (55.1–58.5) 59.1 (55.9–62.5) 56.7 (54.7–58.4) .060
Sex, No. (%) .0001
 Women 228 (53.9) 19 (8.3) 209 (91.7)
 Men 195 (46.1) 42 (21.5) 153 (78.5)
Ethnicity, No. (%)
 White 293 (69.3) 49 (16.7) 244 (83.3) .051
 Asian 44 (10.4) 3 (6.8) 41 (93.2) .173
 Other 39 (9.2) 2 (5.2) 37 (94.8) —
 African American 20 (4.7) 3 (15.0) 17 (85.0) —
 Hispanic 20 (4.7) 4 (20.0) 16 (80.0) —
 Unknown 7 (1.7) 0 (0) 7 (100) —
Type of cancer, No. (%)
 Gastrointestinal 128 (30.3) 8 (6.3) 120 (93.7) .001
 Hematologic 49 (11.6) 0 (0) 49 (100) .0004
 Breast 46 (10.9) 0 (0) 46 (100) .001
 Brain 44 (10.4) 21 (47.7) 23 (52.3) <.0001
 Lung 43 (10.2) 0 (0) 43 (100) .002
 Skin/melanoma 34 (8.0) 19 (55.9) 15 (44.1) <.0001
 Head and neck 28 (6.6) 8 (28.6) 20 (71.4) .045
 Otherb 21 (5.0) 1 (4.8) 20 (95.2) .336
 Gynecologic 17 (4.0) 1 (5.9) 16 (94.1) .487
 Genitourinary 13 (3.1) 3 (23.1) 10 (76.9) .413
No. of alterations, median (95% 
CI)
4 (3–4) 5 (5–6) 3 (3–4) <.0001
Biopsy site used for testing, No. 
(%)c
.358
 Primary 251 (59.6) 41 (16.3) 210 (83.7)
 Metastatic 170 (40.4) 20 (11.8) 150 (88.2)
Abbreviation: CI, confidence interval; TERT, telomerase reverse transcriptase.
Percentages in the Total Patients column are based on the total number of patients (n =423); percentages in the next 2 columns are based on the 
numbers in the Total Patients columns. Bolded values are significant.
a
Fisher’s exact test was used for categorical variables, and Mann-Whitney tests were used for linear variables (age at diagnostic and number of 
alterations). For ethnicity, P values were calculated for the 2 most common ethnicities.
bOther includes the following: sarcomas (n =6), fibromatosis (n =2), neurofibromas (n =2), neuroendocrine tumors (n =2), and unknown primaries 
(n =9).
cAll were tested with the FoundationOne assay; the biopsy site was unknown for 2 patients.
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TABLE 2
Multivariate Analysis of Characteristics Associated With TERT Promoter Alterations
Characteristic
TERT Promoter Alterations (n =61 
[14.4%])
TERT Promoter Wild Type (n 
=362 [85.6%]) Wald Statistic Pa
Sex, No. (%) 4.67 .031
 Women (n =228) 19 (8.3) 209 (57.7)
 Men (n =195) 42 (21.5) 153 (42.3)
Type of cancer, No. (%)
 Gastrointestinal (n =128) 8 (6.3) 120 (93.7) 1.51 .219
 Hematologic (n =49) 0 (0) 49 (100) 0 .997
 Breast (n =46) 0 (0) 46 (100) 0 .997
 Brain (n =44)b 21 (47.7) 23 (52.3) 11.8 .001
 Lung (n =43) 0 (0) 43 (100) 0 .997
 Skin/melanoma (n =34) 19 (55.9) 15 (44.1) 10.5 .001
 Head and neck (n =28) 8 (28.5) 20 (71.5) 1.8 .184
No. of alterations, median (95% CI) 5 (5–6) 3 (3–4) 14.5 .0001
Abbreviation: CI, confidence interval; TERT, telomerase reverse transcriptase.
All percentages are based on the total number of patients with the variable. Bolded values are significant.
aA logistic regression model was used. Variables with P <.05 in the univariate model (Table 1) were included in the multivariate model. The Wald 
test is a way of testing the significance of variables in a statistical model; the higher the Wald statistic is, the higher the association is in the model.
b
Mainly glioblastomas.
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TABLE 4
Overall Survival Analysis: Univariate and Multivariate Correlates
Variable
Univariate Multivariate
HR (95% CI) Pa HR (95% CI) Pb
Alterationsc
 TERT promoter 0.441 (0.22–0.88) .017 0.635 (0.31–1.31) .220
 TP53 0.506 (0.27–0.94) .027 0.637 (0.33–1.23) .179
 CDKN2A/B 0.404 (0.20–0.80) .008 0.613 (0.29–1.31) .207
No. of alterations ≥ 4 0.242 (0.11–0.53) .0001 0.337 (0.15–0.78) .012
Abbreviations: CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; CI, confidence interval; HR, hazard ratio; TERT, telomerase reverse 
transcriptase; TP53, tumor protein 53.
The bolded value is significant.
a
The log-rank test was used. Only significant variables are represented in the univariate analysis.
bA Cox regression model was used. The median overall survival was not reached at the time of this analysis. The median follow-up time from 
diagnosis was 27.3 months (95% CI, 23.2–31.4 months).
c
Patients with alterations in the TERT promoter, TP53, or CDKN2A/B did worse than those without alterations; patients with 4 or more alterations 
did worse than those with fewer alterations.
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